Orchestrating cell and gene therapy logistics is complex and susceptible to variability at each point of the supply chain. When shipments are life-critical, delays and oversights can be fatal. As operations scale from small populations in early-phase clinical trials to larger populations in late-stage trials and commercial launch, your supply chain complexity and risk increases.…
The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, you need an advanced approach to overcome barriers to on-time delivery. In our more than 30 years of experience managing the collection and delivery for time-sensitive cell therapies around the…
As your therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity—and risk—increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain logistics partner. Keep these key considerations top of mind as you evaluate whether potential…
HLA matching in the development of leading-edge allogeneic therapeutics and cellular therapies—and hematopoietic stem cell transplantation (HSCT)—isn’t only about finding the best matches. It’s also about avoiding mismatches that could result in less optimal patient outcomes. During this on-demand webinar, you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal. You’ll…
View this on-demand webinar for an in-depth discussion on patient outcomes tracking through registries and how leveraging patient outcomes data collected from the first-generation of approved cell and gene therapies can inform the advancement of future cell and gene therapy products. Also included is a Q&A session between live webinar attendees and the following experts:…
As your cell and gene therapies move from early-phase clinical trials to commercialization, your supply chain complexity—and risk—increases. Anticipating setbacks and planning for their solution requires a specialized and collaborative approach with your supply chain partner. During this on-demand webinar, you’ll hear from industry experts who offer insights into developing a commercial supply chain for emerging autologous and allogeneic…
View this on-demand webinar to learn how to increase potential for long-term success and ensure donor pool sustainability in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to…
View this on-demand webinar for an in-depth discussion of efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes. A 20-min presentation by Martin Maiers, MS, Vice President of Biomedical Informatics, CIBMTR® (Center for International Blood and Marrow Transplant Research®) is followed by a 40-min Q&A session featuring the following well-known…
With the introduction of innovative cell and gene therapies to market, scalable commercial supply chain strategies are critical to successfully delivering these therapies to patients. The delivery of cell and gene therapies depends on well-designed supply chains. Scaling your supply chain up to achieve this requires having, or finding partners with, proven experience in navigating…
